The GafD lectin of the G (F17) fimbriae of diarrhea-associated Escherichia coli was overexpressed and purified from the periplasm of E. coli by affinity chromatography on GlcNAc-agarose. The predicted mature GafD peptide comprises 321 amino acids, but the predominant form of GafD recovered from the periplasm was 19,092 Da in size and corresponded to the 178 N-terminal amino acid residues, as judged by mass spectrometry and amino acid sequencing, and was named ⌬GafD. Expression of gafD from the cloned gaf gene cluster in DegP-, Lon-, and OmpT-deficient recombinant strains did not significantly decrease the formation of ⌬GafD. The peptide was also detected in the periplasm of the wild-type E. coli strain from which the gaf gene cluster originally was cloned. We expressed gafD fragments encoding C-terminally truncated peptides. Peptides GafD1-252, GafD1-224, GafD1-189, and the GafD1-178, isolated from the periplasm by affinity chromatography, had apparent sizes closely similar to that of ⌬GafD. Only trace amounts of truncated forms with expected molecular sizes were detected in spheroplasts. In contrast, the shorter GafD1-157 peptide was detected in spheroplasts but not in the periplasm, indicating that it was poorly translocated or was degraded by periplasmic proteases. Pulse-chase assays using gafD indicated that ⌬GafD was processed from GafD and is not a primary translation product. The ⌬GafD peptide was soluble by biochemical criteria and exhibited specific binding to GlcNAcagarose. Inhibition assays with mono-and oligosaccharides gave a similar inhibition pattern in the hemagglutination by the G-fimbria-expressing recombinant E. coli strain and in the binding of [ 14 C]⌬GafD to GlcNAc-agarose. ⌬GafD bound specifically to laminin, a previously described tissue target for the G fimbria. Our results show that a soluble, protease-resistant subdomain of GafD exhibits receptor-binding specificity similar to that for intact G fimbriae and that it is formed when gafD is expressed alone or from the gaf gene cluster.
Bacterial adhesion to epithelial and subepithelial surfaces is a prerequisite for colonization of mammalian tissues by pathogenic bacterial species as well as by members of the normal bacterial flora. Pathogenic and commensal strains of Escherichia coli express a variety of fimbrial types with characteristic receptor-binding specificities and serological properties. In the best-characterized fimbrial filament, the P fimbriae of uropathogenic E. coli, the globoside-binding PapG adhesin is a minor component of the filament and is located in the tipassociated fibrillum of the P fimbria (23) . Although detailed studies on P-fimbrial biogenesis have increased our understanding of bacterial adhesive structures (reviewed in reference 48) , it has remained uncertain how well the P fimbria serves as a structural model for other fimbrial types. For example, the mannoside-binding FimH lectin of the E. coli type 1 fimbria is located on specific sites along the fimbrial filament as well as at the fimbrial tip (1, 18, 22) .
It has remained an open question whether the carbohydratebinding specificity of fimbrial filaments is dictated by the lectin peptide alone or whether the other components of the fimbrial filament also influence binding. The mannoside-binding specificity of the FimH lectin in different enterobacterial species has been, by complementation assays, found to be influenced by the fimbrial shaft (31) . On the other hand, variability in type 1 fimbria binding to mannosides and nonmannoside targets has been found to result solely from sequence variations in FimH (37, 45, 47) , and purified, aggregated SfaS lectin has been shown to exhibit sialic acid-binding activity (32) . PapG, FimH, and the G-fimbrial lectin GafD have been expressed as fusions to maltose-binding protein (14, 40, 54) and have been shown to exhibit the correct mono-or disaccharide binding. Hence, several reports strongly indicate that carbohydrate-binding specificity relies on the lectin.
The correct biosynthesis of P and type 1 fimbriae requires the periplasmic chaperones PapD and FimC, which form complexes with lectin proteins PapG and FimH, with the other minor fimbrial proteins, and with major fimbrial subunits PapA and FimA (reviewed in reference 48). PapD has been proposed to protect PapG from proteolytic cleavage, prevent misassembly of PapG in the periplasm, and facilitate import and folding of subunits in the periplasm (19, 49) . PapD binds to a hydrophobic C-terminal motif in PapG to form a 1:1 complex, whereas the N terminus of PapG is important for receptor binding (14, 15, 24, 49) . The X-ray structure of the FimC-FimH chaperone-adhesin complex, resolved recently by Choudhury and coworkers (8) , showed that the FimH lectin consists of two domains connected by a short linker region. The N-terminal receptor-binding domain of FimH accommodates the carbo-hydrate-binding pocket at the distal tip of the domain, and the C-terminal fimbrillin-binding domain binds to the chaperone and subsequently anchors the adhesin to the fimbrial shaft. In the absence of specific chaperones, fimbrial subunits are proteolytically processed by the periplasmic DegP protease and other so far unidentified proteases (3, 51, 57) . C-terminally truncated receptor-binding forms of fimbrial minor proteins have been detected in the periplasm of recombinant E. coli expressing the adhesin gene or chaperone-deficient fimbrial gene clusters; the coexpression of the chaperone significantly decreases the rate of proteolysis of fimbrial proteins in E. coli periplasm (15, 17-19, 26, 46, 57) .
Due to aggregation, complex purification procedures, and sensitivity to proteolytic cleavage, few fimbrial adhesins have been purified for binding or structural analysis. Moch and coworkers (32) purified the sialic acid-binding SfaS adhesin from the S fimbria of E. coli; the lectin was, however, aggregated into complexes of an apparent molecular weight of Ͼ10 6 . PapG and FimH have been affinity purified from the bacterial periplasm as a complex with their specific chaperones PapD and FimC (8, 15, 19, 54) . Recently, two independent reports have shown that stable forms of FimH can be obtained in the periplasm of E. coli by fusing the C terminus of FimH with a polyhistidine tag or a fimbrillin-derived peptide; these fusion proteins apparently are resistant to proteolysis (4, 44) .
The G fimbria belongs to the closely related F17 family of fimbriae that are present on bovine enteropathogenic and septicemic E. coli and that bind to the intestinal brush border as well as to the basement membrane (9, 28, 29, 40, 41, 43) . In contrast to type 1 and P fimbriae, which are encoded by chromosomal gene clusters comprising 9 and 11 genes (15, 22) , the fimbriae in the F17 family are encoded by only four chromosomal genes (27) . Two of the f17 gene products (F17A and F17G) are components of the fimbrial filament, the major fimbrillin and the adhesin (28, 29) . It has been suggested that F17C is an outer membrane usher needed for translocation of subunits across the outer membrane (27) and that the fourth protein, F17D, has amino acid sequence homology to the prototype chaperone PapD and hence should be considered a fimbrial chaperone (16, 24) .
In this paper, we describe the construction and purification of a soluble, nonfusion form of the G-fimbrial GlcNAc-binding GafD lectin of E. coli in the absence of its chaperone. Such soluble fimbrial peptides may be useful in the analysis of structure-function relationships in fimbrial adhesins and as convenient antiadhesive vaccine antigens.
MATERIALS AND METHODS
Bacteria and plasmids. The G-fimbriate E. coli strains IHE11165, IHE11088 (pRR-5), and IHE11088(pHUB110) have been described earlier (38, 41, 56) . Plasmid pRR-5 contains the complete gaf gene cluster from E. coli strain IHE11165 on a 7-kb DNA fragment in pACYC184 (38) , and pHUB110 contains a 6-bp in-frame deletion within the coding region of gafD, resulting in G fimbriae lacking GlcNAc-binding capacity (40) . pHUB113 (40) contains the gafD reading frame cloned into pUC19. Type 1 fimbria-expressing E. coli strain EH826 and DegP-deficient E. coli strain KS474 have been described (39, 50) . E. coli strain BL21 DE3 (ompT lon) and expression vector pET-22b(ϩ) were from Novagen Inc. (Madison, Wis.) . The bacteria were cultivated at 37°C in Luria broth (42) containing the appropriate antibiotics.
Expression and purification of the GafD constructs. The DNA fragment encoding the entire GafD peptide (GafD1-321) on pHUB113 was cloned as a BamHI-HindIII fragment into pET-22b(ϩ) to obtain plasmid pKJ1. The gene fragments encoding C-terminally truncated peptides GafD1-252, GafD1-224, GafD1-189, GafD1-178, and GafD1-157 were amplified by PCR using plasmid pHUB113 as a template. The universal pUC19 primer was used as the 5Ј primer; the 3Ј primers of each construct were designed on the basis of the nucleotide sequence of gafD (40) and contained a stop codon and a HindIII site. After restriction with BamHI and HindIII, the DNA fragments were ligated into BamHI-and HindIII-digested pET-22b(ϩ) and transformed into E. coli BL21 DE3. Restriction enzymes were used according to the manufacturers' instructions (New England Biolabs, Inc., Beverly, Mass.; Promega, Madison, Wis.), and routine methods were used for PCR, DNA ligation, and plasmid transformation (42) . Expression of the gafD constructs in E. coli BL21 DE3 was performed essentially as described by Studier and coworkers (52) and the manufacturer's instructions (Novagen Inc.). Briefly, bacteria were cultivated in 20 ml of Luria broth containing ampicillin (75 g/ml) to an optical density at 600 nm (OD 600 ) of 1.0, washed twice with M9 (42) salt solution, and starved for 1 h at 37°C in 10 ml of M9 solution containing 1 mM isopropyl-␤-D-thiogalactopyranoside (IPTG), 0.4% (vol/vol) glycerol, and ampicillin. In some experiments, a mixture of inhibitors of serine and cysteine proteases (Complete; Boehringer Mannheim) was added to the induction mixture as recommended by the manufacturer. Cells were collected and incubated further for 30 min at 37°C in 2 ml of M9 supplemented with 200 g of rifampin/ml. The bacterial cells were then pulse-labeled by adding 100 l of the 14 C-amino acid mixture (Amersham Life Science, Buckinghamshire, United Kingdom) and by further incubation for 1 h. Samples for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis and autoradiography were taken immediately and at 1-to 10-min intervals after the addition of 14 C-amino acids. The cells were chased by adding 1 ml of Luria broth and by incubating them for 20 min at 37°C and then washed twice with M9 solution; periplasmic peptides were released by an osmotic shock procedure (7) . For expression on a larger scale, the cells expressing gafD were grown in Luria broth without starvation, rifampin, and 14 C labeling to an OD 600 of 1.0, induced with 1 mM IPTG, and further incubated for 2 h at 37°C. Samples of the cells, spheroplasts, and of the corresponding periplasms were analyzed by SDS-PAGE in 15% (wt/vol) slab gels (25) and by autoradiography or Western blotting (55) . In autoradiography, radioactivity at a level of 7,000 dpm/sample was loaded on the gel. Bacterial cells were converted into spheroplasts by treatment with lysozyme and EDTA as described earlier (5). Plasmolysis was achieved by resuspending the collected cells in ice-cold 20% glucose in 10 mM Tris-HCl, pH 8.0 (40) . Lysozyme was then added to a concentration of 100 g/ml followed by two volumes of ice-cold 1.5 mM EDTA, pH 7.5, within 10 min. The cells were kept on ice for 15 min, the formation of spheroplasts was confirmed microscopically, and then the cells were centrifuged. The spheroplasts were resuspended into 480 l of M9 solution or 10 mM Tris-HCl, pH 7.5, and stored at Ϫ20°C. For affinity purification of the GafD and the GafD constructs, the periplasm was mixed with N-acetyl-D-glucosamine (GlcNAc)-agarose beads (Sigma, St. Louis, Mo.), the slurry was rocked slowly for 16 h at 4°C, and the periplasm-agarose mixture was packed into a column. Unbound material was removed by washing with phosphate-buffered saline (PBS), pH 7.1, and peptides bound to the GlcNAc-agarose particles were eluted in PBS containing 5% (wt/vol) GlcNAc (Sigma) (GlcNAc-PBS). Gel filtration through a PD10 column (Pharmacia) was used to remove the carbohydrate from the GafD peptide. For expression of gafD from the gaf gene cluster, plasmid pRR-5 was transformed into E. coli strains BL21 DE3, KS474, and IHE11088 and bacteria were grown in Luria broth as described above, without IPTG induction. Expression of GlcNAc-binding G fimbriae in these strains was verified by agglutination of GlcNAc-agarose particles.
Immunological methods. Antiserum against the purified GafD peptide was raised in rabbits using standard procedures. The antiserum raised against the purified G-fimbrial filaments of E. coli has been described elsewhere (38) . Agglutination of bacterial cells in anti-GafD antisera was performed as described previously (40) . For Western blotting, purified fimbriae available from previous work (39, 40) , the purified GafD peptides, periplasmic peptides, whole cells, and spheroplasts were analyzed by SDS-PAGE and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, Calif.) using a semidry transfer apparatus (Pharmacia) at 0.9 mA/cm 2 for 2 h. After the transfer, the membranes were quenched with 2% (wt/vol) bovine serum albumin (BSA) in PBS for 18 h at room temperature. Polypeptides were visualized by staining with anti-G fimbria or anti-GafD peptide antibodies (diluted 1/1,500 in PBS containing 1% BSA). Bound antibodies were visualized by alkaline phosphatase-conjugated secondary antibodies (Dakopatts, Glostrup, Denmark) diluted 1/2,000 in PBS-BSA and a phosphatase substrate containing nitroblue tetrazolium (Sigma) and 5-bromo-4-chloro-3-indolyl-1-phosphate (Sigma).
Binding and inhibition assays. Hemagglutination and inhibition assays using endo-␤-galactosidase-treated human erythrocytes were performed as previously described (38, 56) . In the binding assays with the [ 14 C]GafD constructs, 50 l of the periplasm from pulse-labeled cells was incubated with 50 l of the GlcNAcagarose or amylose-agarose (New England Biolabs) particle suspension for 30 min in Eppendorf tubes over crushed ice. The particles were washed three times for 5 min in PBS, and the radioactivity remaining on the particles was determined in an LKB 1409 liquid scintillation counter (Wallac, Turku, Finland). In inhibition assays, the carbohydrates were added to the incubation buffer at a final concentration of 20 mM. The carbohydrates tested as inhibitors were from Sigma. The binding of the purified GafD peptide to laminin immobilized on microtiter plates was assessed by a modified enzyme-linked immunosorbent assay as described earlier (58) . The microtiter plate was coated with laminin at a concentration of 25 g/ml, the GafD peptide was used at a final concentration of 5 to 150 nM, the incubation time with the purified GafD peptide was 4 h, and the anti-GafD peptide serum was used at the dilution of 1/2,000 in PBS containing 0.05% (vol/vol) Tween 20. For a control, the binding of GafD to immobilized BSA (25 g/ml) was assessed. External calibration was performed with horse heart myoglobin (Sigma). For protein sequencing, an aliquot corresponding to approximately 50 pmol of protein was concentrated to 30 l in a vacuum centrifuge and subjected to Edman degradation in a Procise 494A protein-sequencing system (Applied Biosystems, Perkin-Elmer, Foster City, Calif.). Protein concentration was estimated spectrophotometrically as described previously (36) . Ultracentrifugation was performed for 100 min at 100,000 ϫ g and 4°C in a 50 Ti rotor in an L8 ultracentrifuge (Beckman Instruments Inc., Palo Alto, Calif.).
Protein sequence analysis. The amino acid sequences of GafD1-321 and GafD1-178 were sent to the ExPASy SWISS-MODEL automated protein modeling server (version 3.5; Swiss Institute of Bioinformatics [http://www.expasy.ch/ swissmod]) (13) and modeled without user-defined templates as well as with FimH (1QUN.pdb; Structural Bioinformatics Protein Databank code 1QUN) of the FimC-FimH chaperone adhesin complex as the template (8) .
Amino acid sequence accession numbers. The amino acid sequences of GafD, F17-D, FimH, PapG, MrkD, and CooD are deposited at EMBL/GenBank under the accession no. AAA69514, AAC45720, S56545, AAA24290, AAA25098, and CAA54230, respectively (10, 11, 20, 27, 30, 37, 40) .
RESULTS
Purification and chemical properties of ⌬GafD. We cloned the gafD gene on pHUB113 as a BamHI-HindIII fragment into expression plasmid pET-22b(ϩ). In the plasmid obtained, pKJ1, gafD is expressed with its own Shine-Dalgarno and leader sequences, and, due to the stop codons upstream and downstream of the gafD reading frame, the peptide lacks the PelB leader sequence as well as the His tag sequence encoded by the vector. We first purified 14 C-labeled GafD from the periplasm of rifampin-treated and pulse-labeled E. coli BL21 DE3(pKJ1) cells using affinity chromatography on GlcNAcagarose. We tested the binding of 14 C-labeled periplasmic peptides to GlcNAc-agarose and, as a control, to amylose-agarose. With 50 l of the labeled periplasm and 50 l of the resin suspension, a radioactivity of 20,818 cpm was bound to the GlcNAc-agarose whereas only 329 cpm was bound to the amylose-agarose, indicating specificity for GlcNAc in the binding.
Autoradiographic analysis of the [ 14 C]GafD binding to GlcNAc-agarose is shown in Fig. 1A , and SDS-PAGE analysis of purified GafD1-321 and GafD1-178 expressed in nonlabeled E. coli BL21 DE3 is shown in Fig. 1B . After the pulse-labeling of rifampin-treated cells with 14 C-amino acids, three radioactive peptides were detected in the periplasm of BL21 DE3 (pKJ1) (lane 1 in Fig. 1A) . The minor peptide with the apparent molecular mass of 32 kDa was bound to the GlcNAcagarose (lane 3) and eluted in GlcNAc-PBS, suggesting that it was GafD (calculated size, 33,889 Da). The peptide of 30 kDa not bound to the GlcNAc-agarose (lane 2) was considered to be ␤-lactamase encoded by the vector on the basis of its migration properties in SDS-PAGE gel and its lack of reactivity with GlcNAc-agarose (lane 3) and with anti-GafD antibodies (see below). The major radioactive peptide in the periplasm was a peptide with an apparent size of 20 kDa that bound to the GlcNAc-agarose (lane 3) and that was eluted in GlcNAc-PBS (lane 1 in Fig. 1B) ; the affinity-purified 32-kDa minor peptide was clearly visible only when expressed on a larger scale (lane 1 in Fig. 1B ). For comparison, the affinity-purified proteolytically resistant peptide GafD1-178 is shown in lane 2. The addition of Complete, a cocktail of various inhibitors of serine and cysteine proteases, to the induction mixture did not prevent the degradation (data not shown). The sequencing of the 20-kDa peptide gave a single N-terminal sequence, AVSFIG, which perfectly matches the N-terminal sequence of the mature GafD (40) . The peptide was therefore named 1 and 4) , the mutated G fimbria without lectin activity isolated from E. coli HB101(pHUB110) (lanes 2 and 5), and the type 1 fimbria from E. coli EH826 (lanes 3 and 6) . The migration distances of molecular weight markers are indicated on the left; those of the GafD and the GafA peptides are indicated on the right.
⌬GafD. Mass spectrometric analysis of the ⌬GafD peptide gave a mass of 19,092 ϩ/Ϫ 20 Da, which indicates that the C-terminal residue in ⌬GafD is Thr-178 (calculated molecular mass, 19,074 Da). An aliquot of the affinity-purified [ 14 C] ⌬GafD was gel filtered to remove excess GlcNAc, diluted 1/2 in PBS, and ultracentrifuged for 100 min at 100,000 ϫ g; the radioactivity in the supernatant was 29,740 cpm/ml before and 28,410 cpm/ml after the ultracentrifugation. This indicates that [ 14 C]⌬GafD was soluble and not sedimented.
Production and specificity of the anti-GafD antibodies. We immunized rabbits with the affinity-purified ⌬GafD and assessed the specificity of the obtained antibodies by Western blotting (Fig. 1C) . The antiserum raised against purified G fimbriae detected the GafA fimbrillin as well as GafD in the G fimbriae purified from E. coli HB101(pRR-5) and HB101 (pHUB110) (lanes 1 and 2 in Fig. 1C ) but did not react with the type 1 fimbrial peptides tested as the control (lane 3 in Fig.  1C ). Plasmid pRR-5 expresses the complete G-fimbrial gene cluster, whereas the 6-bp in-frame deletion within the coding region of gafD in plasmid pHUB110 results in nonfunctional G-fimbrial filaments. The antibodies raised against the purified GafD detected the full-length GafD peptide in the two G-fimbrial preparations. The truncated 20-kDa ⌬GafD form was not detected in G-fimbrial preparations (lanes 4 and 5 in Fig. 1C) .
Expression of gafD in pulse-labeled cells. To determine whether ⌬GafD is a posttranslational processing product from GafD or a primary translation product, we analyzed by SDS-PAGE and autoradiography pulse-labeled cells of E. coli BL21 DE3(pKJ1). Samples were taken immediately after the addition of 14 C-labeled amino acids and at short intervals up to 1 h 30 min after the addition of the label. Autoradiographic analysis of peptides expressed in the pulse-labeled cells are shown in Fig. 2A . A major polypeptide of 32 kDa corresponding to intact GafD and trace amounts of 20-and 30-kDa peptides corresponding to ⌬GafD and vector-encoded ␤-lactamase, respectively, were detected immediately after addition of the label (lane 1 in Fig. 2A ). The amount of ⌬GafD increased over time, and the peptide was clearly visible 1 h 30 min after addition of the 14 C label (lane 2 in Fig. 2A ). Expression of gafD from the gaf gene cluster in various host strains and in wild-type strain E. coli IHE11165. To analyze whether ⌬GafD was formed in other host backgrounds, plasmid pRR-5 was introduced into the following E. coli host strains: BL21 DE3, which is deficient in cytoplasmic protease Lon and outer membrane protease OmpT, KS474, which lacks periplasmic protease DegP, and IHE11088, which is a clinical isolate previously shown to support fimbrial synthesis from plasmid pRR-5 (41) . A Western blot of periplasmic extracts from these strains is shown in Fig. 2B , which also shows the blot obtained from G-fimbriated clinical isolate E. coli IHE11165, which expresses gafD from the chromosomal gaf gene cluster and which was used as the source for cloning the gaf gene cluster (38) . GafD appeared as a minor 32-kDa peptide and ⌬GafD appeared as the major form in the periplasmic extracts of all the strains tested (lanes 1 to 3 in Fig. 2B ), including strain IHE11165 (lane 5). The periplasmic forms of GafD expressed from E. coli BL21 DE3(pKJ1) are shown for comparison in lane 4. As judged by bacterial agglutination in anti-GafD antiserum and of GlcNAc-agarose particles, the strains tested expressed GafD lectin on their surfaces (data not shown). The results show that ⌬GafD was accumulated in the periplasm concomitantly with the expression of functional G fimbrial filaments in the clinical isolate of E. coli as well as in the recombinant strains.
Expression and characterization of C-terminally truncated GafD constructs.
To analyze the size requirements of ⌬GafD expression and binding activity in more detail, we constructed deletions in the 3Ј region of gafD in pKJ1 and analyzed the peptide products in rifampin-treated, starved, and pulse-labeled E. coli BL21 DE3. The constructs are schematically shown in Fig. 3A , and examples of autoradiographic analysis of their expression in E. coli cells, spheroplasts, and periplasm are shown in Fig. 3B . In whole cells and in spheroplasts, the complete GafD molecule ([ 14 C]GafD1-321) migrated mainly as a 32-kDa peptide but appeared in the periplasm mainly as a 20-kDa peptide (lanes 1 through 3 in Fig. 3B) . [ 14 C]GafD1-157 (calculated size, 16,825 Da) was detected in the cells and spheroplasts as a 15-kDa peptide and was not found in the periplasm of pulse-labeled cells (lanes 4 through 6 in Fig. 3B ). The GafD1-252 (26,348 Da), GafD1-224 (23,544 Da), GafD1-189 (20,216 Da), and GafD1-178 (19,074 Da) peptides were detected in cells, spheroplasts, and periplasm mainly as peptides with apparent sizes of 20 kDa; GafD1-252 and GafD1-178 are shown in lanes 7 through 12 in Fig. 3B . GafD1-178 was subjected to mass spectrometric analysis, and the result gave a mass of 19,113 Da, which is close to its calculated molecular mass. The 32-, 20-, and 15-kDa peptides present in whole-cell samples reacted in Western blot analysis with anti-GafD antibodies (data not shown), indicating that these peptides indeed were different forms of GafD.
Binding characteristics of ⌬GafD. We then assessed the carbohydrate sensitivity of the binding of ⌬GafD to GlcNAcagarose. D (Table 1) . These carbohydrates exhibited a similar inhibition pattern in the hemagglutination by G-fimbriate E. coli cells of erythrocytes with terminal GlcNAc residues on their surfaces ( Table 1) . The basement membrane glycoprotein laminin was recently identified as a tissue target for the G fimbria (41) . We therefore assessed by enzyme-linked immunosorbent assay methodology whether ⌬GafD binds to laminin immobilized on microtiter plates (Fig. 4) . A dose-dependent binding to laminin was evident; no significant binding to BSA was detected (Fig. 4A) . (Fig. 4B) .
The binding to laminin was inhibited by 50 mM N-acetyl-D-glucosamine but not by 50 mM N-acetyl-D-galactosamine

DISCUSSION
We describe here a soluble, C-terminally truncated form of the GafD fimbrial lectin that was named ⌬GafD. The truncated 20-kDa form was present in the periplasm of G-fimbriaexpressing E. coli strains but was not incorporated into the G-fimbrial filament. Pulse-chase experiments indicated that ⌬GafD is a proteolytic product of GafD rather than a primary translation product. ⌬GafD shows receptor-binding characteristics similar to those shown by the complete fimbrial filament, and our results support the concept that the carbohydratebinding specificity of a gram-negative fimbria is dictated by the lectin subunit alone (14, 37, 45, 47) . The receptor-binding region of GafD is apparently located at the N terminus of the molecule. This paper is the first to report on the expression and purification on a larger scale of a soluble nonfusion form of a fimbrial lectin. The biotechnological application potential of soluble adhesin forms is high: they could be used in receptor identification or isolation, in production of antiadhesive vaccines, and in structural studies.
The GafD peptide was not processed in the cytoplasm but appeared in the periplasm as ⌬GafD. These findings indicated that the C terminus of GafD is resistant to cytoplasmic proteases but is processed during translocation into or in the periplasm. Overexpressed GafD1-178, GafD1-189, GafD1-224, and GafD1-252 peptides appeared in the cellular, spheroplastic, and periplasmic compartments mainly as the ⌬GafD form, which suggests that the peptides were proteolytically processed to the stable 20-kDa structure already in the cytoplasm. a MIC of the carbohydrate required to prevent hemagglutination of endo-␤-galactosidase-treated human erythrocytes (56) .
b The inhibitory effect was tested at a 20 mM concentration and is given as the percent inhibition compared to the binding in the absence of added carbohydrate.
c No inhibition at the highest test concentration.
were detected in Western blots of the periplasm of E. coli BL21 DE3 cells overexpressing GafD. The peptides were also detected when GafD was expressed from the entire gaf gene cluster in plasmid pRR-5 in host strains deficient in proteases DegP, Lon, and OmpT as well as in clinical isolate E. coli IHE11088, previously shown to support fimbrial synthesis from plasmid pRR-5 (41) . In addition, we detected ⌬GafD in the periplasm of wild-type clinical isolate E. coli IHE11165, from which the gaf gene cluster was originally cloned, which suggests that the ⌬GafD form may be a natural product of the gaf gene cluster. All strains with the gaf gene cluster also expressed functional G fimbriae on their surfaces, further indicating that ⌬GafD is not a result of the overexpression technology. However, G-fimbrial filaments contained full-size GafD but not ⌬GafD, which indicated that the C-terminally truncated ⌬GafD is not polymerized into the fimbrial filaments. Coexpression of GafD1-321 with G-fimbrial putative chaperone GafB (16, 24) or P-fimbrial chaperone PapD in E. coli BL21 DE3, according to procedures used for expression of the PapG-PapD complex (46), did not prevent C-terminal degradation of GafD (data not shown). In this respect GafD differs from PapG, FimH, and the MrkD adhesin of type 3 fimbriae of Klebsiella pneumoniae, which can form complexes with and utilize PapD in assembly into the fimbrial tip (11, 17, 19, 46, 53) . The results suggest that the secretion and folding of ⌬GafD to the functionally correct conformation in the periplasm are not dependent on GafB function in the expression system.
We detected ⌬GafD in host cells lacking proteases DegP, Lon, and OmpT, which indicates that the C-terminal degradation of GafD is mediated by some other, so far unidentified proteases. Very little data on the target sequences of E. coli proteases exist; they seem to recognize a target sequence in combination with a target protein conformation (reviewed in reference 12). We found no significant homology of the GafD region around residue Thr-178 to target sequences of E. coli proteases (12) . The exact cleavage sites were not determined for the periplasmic C-terminally truncated forms of FimH, PapG, and CooD previously observed (15, 18, 57) , which makes it more difficult to infer why GafD is cleaved up to residue 178 but not more extensively to the N-terminal region of this site. The X-ray structure of the FimC-FimH complex, recently presented by Choudhury and coworkers (8) , reveals that FimH is composed of two domains, a mannose-binding lectin domain that comprises the 156 N-terminal residues and a chaperone-binding C-terminal domain that comprises residues 160 to 279. Recently, Schembri and coworkers expressed in the periplasm of E. coli the 156-mer receptor-binding domain of FimH fused to a polyhistidine tail (44) . In another recent study, the 13 N-terminal residues of FimG were fused to the C terminus of FimH and the modified FimH was expressed in the periplasm (4). These reports suggest that protection of the C terminus of FimH facilitates proper folding and renders the peptide proteolytically resistant in the periplasm. In the primary sequence alignment of GafD and FimH, the Thr-178 of GafD is located at the position of the flexible linker region in FimH. However, ⌬GafD shows only 21.5% identity to the N-terminal domain of FimH, which does not facilitate the modeling of the three-dimensional structure of ⌬GafD on the basis of the FimH structure. We anticipate that GafD, like FimH, has two domains, an N-terminal protease-resistant receptor-binding domain and a C-terminal protease-sensitive one, but that the fine structures of the two lectins differ. The explanation why ⌬GafD is protease resistant and soluble requires the crystal structure of ⌬GafD, which we currently are solving.
The receptor-binding region of the GafD lectin is apparently located within the 178 N-terminal amino acids of the mature protein. GafD resembles PapG, DraE, and the FimH fimbrial adhesin of E. coli in that the N-terminal part of the adhesin molecule is important for the receptor-binding activity (6, 8, 14, 21, 54) . Such an arrangement, however, is not shared by all fimbrial adhesins (35) . In the sialic acid-binding SfaS minor protein of the S fimbriae, the receptor-binding region was mapped to the C-terminal part of the SfaS molecule (33). We have previously described in pHUB110 an in-frame deletion of the codons for amino acid residues Gly-94 and Thr-95, which abolishes GlcNAc binding by GafD (40) . This mutated GafD peptide was detected as a component of purified G fimbriae, indicating that the nonbinding phenotype resulted from destruction of binding activity rather than from lack of GafD incorporation into the fimbriae.
⌬GafD specifically bound to GlcNAc-agarose, and the binding was inhibited by GlcNAc but not by GalNAc. We also observed that purified ⌬GafD binds to laminin, a glycosylated basement membrane protein that we recently identified as a tissue receptor for the G fimbriae using isolated fimbriae as well as recombinant E. coli (41) . These results confirm the role of GafD as the GlcNAc-binding fimbrial lectin. The inhibition of ⌬GafD binding to GlcNAc-agarose by carbohydrates exhibited a pattern closely similar to that seen for inhibition of hemagglutination by G-fimbriate E. coli (38, 56) . The GlcNAcdi-, tri-, and -tetrasaccharides diacetylchitobiose [2-acetamido-2-deoxy-4-O-(2-acetamido-2-deoxy)-␤-D-glucopyranosyl)-D-glucopyranose], triacetylchito-triose, and tetraacetylchitotetraose were only slightly more efficient inhibitors of ⌬GafD binding than was GlcNAc-monosaccharide, which indicates that the ␤1-4-linked GlcNAc chains are not well recognized by the receptor-binding region of GafD. Indeed, in laminin, which is recognized by GafD, the terminal GlcNAc residues are ␤1-3 linked to N-acetyllactosamine residues (2). Similar receptor preference has been observed with the G lectin of the F17 fimbriae. Inhibition by glycoproteins of hemagglutination by purified F17 fimbriae or E. coli cells expressing F17 fimbriae has shown that the F17 fimbrial lectin preferentially recognizes oligosaccharides carrying ␤1-3 linked GlcNAc chains and binds only poorly to those having 1-4 and 1-6 linkages (34). As far as it is possible to conclude from these inhibition assays, the carbohydrate-binding specificity of ⌬GafD and that of the G fimbriae are closely similar. We are currently analyzing the function of ⌬GafD in the periplasm of E. coli.
